Gilde Healthcare raises €200 million for new private equity fund - Gilde Healthcare

Gilde Healthcare raises €200 million for new private equity fund

March 7, 2019

Targeting lower mid-market healthcare investments in the Benelux and DACH regions

Utrecht (the Netherlands) and Frankfurt (Germany) – Gilde Healthcare, the European specialist investor in healthcare, today announces that it has raised €200 million for its third private equity fund, Gilde Healthcare Services III. The fund will focus on healthcare providers, suppliers of medical products and service providers in the lower mid-market. The fund operates offices in Utrecht (The Netherlands) and Frankfurt (Germany).

The fund reached its hardcap in a few months’ time and was raised with Dutch institutional investors including, among others, PGGM/Pensioenfonds Zorg en Welzijn and Rabo Corporate Investments and various international fund-of-fund investors. To date, Gilde Healthcare has raised more than €1 billion for its dedicated healthcare investment funds. Examples of recent private equity investments include hospital software provider Performation, integrated telecom solutions provider Zetacom and drug discovery contract research organization MercachemSyncom.

Jasper van Gorp, Managing Partner at Gilde Healthcare: “We are pleased with the high level of interest for our new fund which is testament to our investment strategy and track record. We see a strong deal flow of healthcare providers, suppliers of medical products and service providers in the Benelux and DACH regions. Via our local presence we are well-positioned to source proprietary healthcare transactions in the lower mid-market.”

The new private equity fund is focused on established and profitable businesses in Europe with an EBITDA of between €2-15 million, preferably headquartered in the Benelux or DACH (Germany, Switzerland and Austria) regions.

In addition to capital, Gilde Healthcare provides hands-on support to the management of its portfolio companies, via activities such as implementing a growth strategy and leveraging its deep healthcare industry expertise and international network. Gilde Healthcare believes optimal value creation in healthcare is associated with better care at lower cost.

Recently, Gilde Healthcare strengthened its private equity team with additional experienced investment professionals: Rafael Natanek (previously a partner at Bain Consulting in the European healthcare practice) joined as partner and Boyd Rutten (previously at private equity firm EQT Partners) joined as senior associate.
About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two fund strategies: private equity and venture & growth capital. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies including healthcare providers, suppliers of medical products and service providers, with a primary focus on the Benelux and DACH regions. Gilde Healthcare’s venture & growth fund is focused on fast growing health tech and therapeutics companies based in Europe and North America. https://gildehealthcare.com

Media Contacts

Gilde Healthcare

Jasper van Gorp
Managing Partner
Newtonlaan 91
3584BP Utrecht
The Netherlands
vangorp@gildehealthcare.com
+31 (0)30 219 2533

Dr Fabian Braemisch
Partner DACH-region
Neue Mainzer Strasse 74
60594 Frankfurt
Germany
braemisch@gildehealthcare.com
+49 69 153 255 870

CFF Communications

Jan van Ewijk
+31 (0)20 575 4011
+31 (0)6 14229820
jan.vanewijk@cffcommunications.nl

Aniek Zweers
+31 (0)20 575 4032
+31 (0)6 31973375
aniek.zweers@cffcommunications.nl

Gilde Healthcare portfolio company Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04 at ACR Convergence 2024

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is presenting the results from its positive Phase II trial of LEVI-04 at the American College of Rheumatology's annual...
November 14, 2024

Gilde Healthcare company Noema Pharma Announces First Patients Dosed in Phase 2b Study for Tourette Syndrome

Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global...
October 30, 2024

Gilde Healthcare invests in SynOx Therapeutics and company doses first patients in Phase 3 trial

Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment of Tenosynovial Giant...
October 30, 2024